# ClinicalTrials.gov record NCT07417631

> PeptideScanner retained ClinicalTrials.gov record NCT07417631 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-10, and PeptideScanner's reviewed identity mapping was dulaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07417631-dulaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-10
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07417631-dulaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct07417631-dulaglutide-v1.json
- Content SHA-256: `adcd617c450a95527b4d49a8ca8dab2db1793c7807bd8ab0ca3fe5958b7cd1ea`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT07417631 ([`ctg-observation-nct07417631-2026-07-10-a407914bd3ae`](#source-ctg-observation-nct07417631-2026-07-10-a407914bd3ae))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07417631 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-10, and PeptideScanner's reviewed identity mapping was dulaglutide. ([`ctg-observation-nct07417631-2026-07-10-a407914bd3ae`](#source-ctg-observation-nct07417631-2026-07-10-a407914bd3ae))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07417631 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-10, and PeptideScanner's reviewed identity mapping was dulaglutide. ([`ctg-observation-nct07417631-2026-07-10-a407914bd3ae`](#source-ctg-observation-nct07417631-2026-07-10-a407914bd3ae))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07417631-2026-07-10-a407914bd3ae`](#source-ctg-observation-nct07417631-2026-07-10-a407914bd3ae))

## Sources

<a id="source-ctg-observation-nct07417631-2026-07-10-a407914bd3ae"></a>
- **ClinicalTrials.gov record NCT07417631 · retained source version 2026-07-10:a407914bd3ae9d5283f5f1dacf651a34e90e7eafcd60c31a0e9c0bce38a36947** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07417631) (`ctg-observation-nct07417631-2026-07-10-a407914bd3ae`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07417631." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct07417631-dulaglutide-v1.json SHA-256: adcd617c450a95527b4d49a8ca8dab2db1793c7807bd8ab0ca3fe5958b7cd1ea.